Biophage Pharma prepares to meet increased demand for Beryllium and MELISA(R) testing - Dr. Michel Heyne will become director of the Beryllium Reference Lab to help expedite its INSPQ accreditation



    MONTREAL, Jan. 30 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma Inc.
(Biophage) today announced the hiring of Dr. Michel Heyne as director of its
Beryllium Reference Lab to meet the increasing demand for Beryllium and
MELISA(R) testing. With his vast experience in laboratory testing this eminent
haematologist will help expedite the accreditation process of Biophage's
Beryllium laboratory by the Quebec National Institute of Public Health
(INSPQ).
    Dr. Heyne brings more than 38 years experience in the hematology field to
Biophage. He was an active member of the medical team at Hôpital Hotel-Dieu in
St-Jerome for more than 35 years where he acted as director of the Department
of Internal Medicine, head of Hemato-oncology services, and head of the
Laboratories Department. He was also the founder of the Hematology and
Hemato-oncology laboratories at Hotel-Dieu. For more than 26 years, Dr Heyne
was also a consultant in Hemato-oncology for the Hospital Centers of
Argenteuil and Laurentien.
    Dr. Mandeville, President and CEO of Biophage commented, "We are
extremely pleased to welcome Dr. Heyne to our Immunotox Labs team. Dr. Heyne
brings to Biophage a wealth of experience and expertise in the field of
hematology and laboratory testing as well as an in-depth knowledge of the
field and its basic unmet needs. His extensive network of contacts in North
America and Europe will help our team identify new markets for Beryllium and
MELISA(R) testing."

    About Biophage Pharma Inc.

    Biophage Pharma is a high potential, revenue-driven Canadian
biotechnology company focused on the development of innovative phage-based
products and technologies for the detection and management of bacterial
contaminations. Founded in 1995, Biophage operates three divisions: (1) The
phage therapy division for the management of bacterial contaminations in the
medical, veterinary and environment fields; (2) The Biosensors division for
the development and commercialization of Biosensors, more particularly a
portable PDS(R) Biosensor which is entering in the pre-commercialization
stage; (3) The Immunotox Labs division, which provides services in
Immunogenicity and Immunotoxicity, Nanotoxicity and Ecotoxicology, Beryllium
sensitivity testing and MELISA(R) testing for the detection of sensitization
to more than 200 different allergens including metals, penicillin, gluten and
pollens. (www.biophagepharma.net ; www.immunotoxlabs.net).

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.
    %SEDAR: 00014714EF




For further information:

For further information: Biophage Pharma Inc.: Rosemonde Mandeville,
M.B., Ch.B., PhD., President and Chief Executive Officer, (514) 496-1488,
rosemonde.mandeville@biophagepharma.net; Renmark Financial Communications
Inc.: Investor relations: Christine Stewart: cstewart@renmarkfinancial.com,
Barbara Komorowski: bkomorowski@renmarkfinancial.com; (514) 939-3989, Fax:
(514) 939-3717, www.renmarkfinancial.com

Organization Profile

BIOPHAGE PHARMA, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890